Coherus BioSciences, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
0.7820
+0.0160 (2.09%)
At close: Jun 3, 2025, 4:00 PM
0.7950
+0.0130 (1.66%)
After-hours: Jun 3, 2025, 6:52 PM EDT
Coherus BioSciences Stock Forecast
CHRS's stock price has decreased by -57.03% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 3 professional analysts, the 12-month price target for Coherus BioSciences stock ranges from a low of $1.05 to a high of $7.00. The average analyst price target of $4.68 forecasts a 498.47% increase in the stock price over the next year.
Price Target: $4.68 (+498.47%)
Analyst Consensus: Buy
* Price targets were last updated on Apr 29, 2025.
Analyst Ratings
The average analyst rating for Coherus BioSciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +795.14% | Apr 29, 2025 |
| UBS | UBS | Hold Maintains $1.5 → $1.05 | Hold | Maintains | $1.5 → $1.05 | +34.27% | Apr 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +795.14% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +795.14% | Jan 23, 2025 |
| Baird | Baird | Buy Maintains $4 → $6 | Buy | Maintains | $4 → $6 | +667.26% | Dec 5, 2024 |
Financial Forecast
Revenue This Year
82.58M
from 266.96M
Decreased by -69.07%
Revenue Next Year
98.92M
from 82.58M
Increased by 19.78%
EPS This Year
-1.04
from 0.25
EPS Next Year
-0.76
from -1.04
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 113.4M | 167.0M | 185.6M | ||
| Avg | 82.6M | 98.9M | 106.8M | ||
| Low | 46.3M | 27.2M | 31.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -57.5% | 102.2% | 87.7% | ||
| Avg | -69.1% | 19.8% | 8.0% | ||
| Low | -82.7% | -67.1% | -67.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.65 | -0.27 | -0.47 | ||
| Avg | -1.04 | -0.76 | -0.62 | ||
| Low | -1.21 | -1.13 | -0.81 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.